; (C) the raw materials and other components for critical drugs and devices; and (D) the public health and national security implications of the current supply chain for critical drugs and devices; (2) convene a public symposium to— (A) analyze the impact of United States dependence on the foreign manufacturing of critical drugs and devices on patient access and care, including in hospitals and intensive care units; and (B) recommend strategies to end United States dependence on foreign manufacturing to ensure the United States has a diverse and vital supply chain for critical drugs and devices to protect the Nation from natural or hostile occurrences; and (3) submit a report on the symposium’s proceedings to the Congress and publish a summary of such proceedings on the public website of the National Academies. (b) Symposium In carrying out the agreement under subsection (a), the National Academies shall consult with— (1) the Department of Health and Human Services, the Department of Homeland Security, the Department of Defense, the Department of Commerce, the Department of State, the Department of Veterans Affairs, the Department of Justice, and any other Federal agencies as appropriate; and (2) relevant stakeholders, including drug and device manufacturers, health care providers, medical professional societies, State-based societies, public health experts, State and local public health departments, State medical boards, patient groups, health care distributors, wholesalers and group purchasing organizations, pharmacists, and other entities with experience in health care and public health, as appropriate. (c) Definitions For the purposes of this section: (1) The term critical — (A) with respect to a device, refers to a device classified by the Food and Drug Administration as implantable, life-saving, and life-sustaining